专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09783500B2 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition 有权
公开(公告)号：US09783500B2
公开(公告)日：2017-10-10
申请号：US15252754
申请日：2016-08-31
申请人： Northwestern University
发明人： Richard B. Silverman , Maris A. Cinelli , Anthony V. Pensa
IPC分类号： C07D215/38 , C07D401/12 , C12N9/02
CPC分类号： C07D215/38 , C07D401/12 , C12N9/0075 , C12Y114/13039
摘要： Various 2-aminoquinoline compounds as can be used, in vivo or in vitro, for selective inhibition of neuronal nitric oxide synthase.

2. 发明申请

US20170252376A1 NUCLEIC ACID CONSTRUCTS INCLUDING A TXNIP PROMOTER FOR THE TREATMENT OF DISEASE 审中-公开
公开(公告)号：US20170252376A1
公开(公告)日：2017-09-07
申请号：US15449593
申请日：2017-03-03
申请人： Wayne State University
发明人： Lalit Singh Pukhrambam
IPC分类号： A61K35/35 , C07K14/62 , C12N9/02 , C07K14/47 , C07K14/475 , C07K14/705 , C12N15/113 , C07K14/65
CPC分类号： A61K35/35 , A61K9/0019 , A61K38/00 , C07K14/47 , C07K14/475 , C07K14/62 , C07K14/65 , C07K14/705 , C07K2319/10 , C12N9/0051 , C12N9/0075 , C12N15/111 , C12N15/1135 , C12N15/1136 , C12N2310/14 , C12N2320/30 , C12N2330/51 , C12Y108/0401 , C12Y114/13039
摘要： Nucleic acids for the treatment of diseases are described. The nucleic acids include a thioredoxin-interacting protein (TXNIP) promoter and a gene that encodes a therapeutic protein or an interfering nucleic acid sequence (e.g., interfering RNA (iRNA sequence)).

3. 发明申请

US20170087221A1 NITRIC OXIDE-MODULATING BONE-TARGETING COMPLEXES 审中-公开
公开(公告)号：US20170087221A1
公开(公告)日：2017-03-30
申请号：US14870465
申请日：2015-09-30
申请人： Elwha LLC
发明人： Mahalaxmi Gita Bangera , Roderick A. Hyde , Muriel Y. Ishikawa , Eric C. Leuthardt , Lowell L. Wood, JR.
IPC分类号： A61K38/44 , C12N9/02 , C12N9/96 , A61K47/48
CPC分类号： A61K38/44 , A61K47/548 , A61K47/64 , A61K47/645 , C12N9/0075 , C12N9/96 , C12Y114/13039
摘要： Compositions and methods are described herein for treating a bone disorder, including a bone-targeting complex including at least a portion of a nitric oxide synthase; a bone-targeting agent; and a linker coupling the at least a portion of the nitric oxide synthase to the bone-targeting agent.

4. 发明授权

US09428550B2 Peptides and methods and uses thereof for preventing retinal disorders 有权
标题翻译：肽及其用于预防视网膜疾病的方法和用途
公开(公告)号：US09428550B2
公开(公告)日：2016-08-30
申请号：US14373073
申请日：2013-01-16
申请人： Governing Council of The University of Toronto
发明人： Paulo Koeberle
IPC分类号： C07K7/06 , A61K38/08 , C07K14/705 , C12N9/16 , C07K14/71 , C12N9/02 , C12N9/12 , C07K14/005
CPC分类号： C07K7/06 , A61K38/00 , A61K38/08 , C07K14/005 , C07K14/705 , C07K14/71 , C07K2319/00 , C07K2319/10 , C12N9/0075 , C12N9/12 , C12N9/16 , C12N2740/16022
摘要： The present disclosure relates to methods and uses of C-terminal peptides for inhibiting neuronal cell death or dysfunction, such as retinal ganglion cell death or dysfunction, treating retinal degenerative disorders, stroke, CNS and PNS insults. The disclosure also relates to the C-terminal peptides, fusion proteins and compositions thereof.
摘要翻译：本公开涉及C末端肽抑制神经元细胞死亡或功能障碍的方法和用途，例如视网膜神经节细胞死亡或功能障碍，治疗视网膜退行性疾病，中风，CNS和PNS侮辱。本公开还涉及C-末端肽，融合蛋白及其组合物。

5. 发明申请

US20140315988A1 COMPOSITIONS AND METHODS FOR REPROGRAMMING EUKARYOTIC CELLS 有权
标题翻译：复制原核细胞的组合物和方法
公开(公告)号：US20140315988A1
公开(公告)日：2014-10-23
申请号：US14322526
申请日：2014-07-02
申请人： CELLSCRIPT, LLC
发明人： Gary Dahl , Anthony Person , Judith Meis , Jerome Jendrisak
IPC分类号： C12N15/85
CPC分类号： C12N5/0696 , A61K38/1709 , A61K38/1816 , A61K38/44 , A61K38/465 , A61K38/50 , A61K48/005 , A61K48/0075 , C07K14/47 , C07K14/4712 , C07K14/505 , C12N9/0075 , C12N9/22 , C12N9/78 , C12N15/117 , C12N15/85 , C12N15/87 , C12N2310/17 , C12N2310/335 , C12N2320/30 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/605 , C12N2501/606 , C12N2501/608 , C12N2506/02 , C12Y114/13039 , C12Y301/04012 , C12Y305/04004
摘要： The present invention relates to methods for changing the state of differentiation of a eukaryotic cell, the methods comprising introducing mRNA encoding one or more reprogramming factors into a cell and maintaining the cell under conditions wherein the cell is viable and the mRNA that is introduced into the cell is expressed in sufficient amount and for sufficient time to generate a cell that exhibits a changed state of differentiation compared to the cell into which the mRNA was introduced, and compositions therefor. For example, the present invention provides mRNA molecules and methods for their use to reprogram human somatic cells into pluripotent stem cells.
摘要翻译：本发明涉及用于改变真核细胞分化状态的方法，所述方法包括将编码一种或多种重编程因子的mRNA引入细胞并将细胞维持在其中细胞存活的条件下，并将导入表达足够量的细胞并足够的时间产生与引入mRNA的细胞相比表现出改变的分化状态的细胞及其组合物。例如，本发明提供mRNA分子及其用于将人体细胞重编程为多能干细胞的方法。

6. 发明申请

US20120308570A1 METHODS FOR TREATING DISEASES 审中-公开
标题翻译：治疗疾病的方法
公开(公告)号：US20120308570A1
公开(公告)日：2012-12-06
申请号：US13319090
申请日：2010-05-06
申请人： Tatiana Kolesnik , Zhihe Kuang , Rowena Sue Lewis , Sandra Elaine Nicholson , Ray Norton
发明人： Tatiana Kolesnik , Zhihe Kuang , Rowena Sue Lewis , Sandra Elaine Nicholson , Ray Norton
IPC分类号： A61K38/17 , C07K7/08 , C07K16/18 , A61K39/395 , A61K38/08 , G01N24/08 , A61P11/00 , A61P29/00 , C12N5/071 , G01N33/566 , G01N33/573 , G01N21/55 , C07K14/435 , A61P11/06
CPC分类号： C07K16/40 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0337 , A61K38/00 , C07K14/47 , C12N9/0075 , C12N15/113 , C12N2310/14 , C12N2310/531 , C12Y114/13039 , G01N2500/02
摘要： The present invention relates to methods of modulating the level of inducible nitric oxide synthase (iNOS) in a cell which comprises administering to the cell a compound which modulates binding of SPRY domain-containing SOCS box protein (SSB) to iNOS, and/or a compound which modulates SSB activity in the cell. Further provided are methods of treating or preventing disease in a subject by modulating the level of iNOS in a cell, as well as compounds which modulate binding of SSB to iNOS and compounds which modulate SSB activity.
摘要翻译：本发明涉及调节细胞中诱导型一氧化氮合酶（iNOS）水平的方法，其包括向细胞施用调节含有SPRY结构域的SOCS盒蛋白（SSB）与iNOS的结合的化合物和/或调节细胞中SSB活性的化合物。还提供了通过调节细胞中iNOS的水平以及调节SSB与iNOS的结合的化合物和调节SSB活性的化合物来治疗或预防受试者的疾病的方法。

7. 发明授权

US07888089B2 eNOS mutations useful for gene therapy and therapeutic screening 有权
标题翻译： eNOS突变可用于基因治疗和治疗筛选
公开(公告)号：US07888089B2
公开(公告)日：2011-02-15
申请号：US12316128
申请日：2008-12-09
申请人： William C. Sessa
发明人： William C. Sessa
IPC分类号： C12N9/02 , C12N1/20 , C12N15/00 , C12P21/04 , C07H21/04
CPC分类号： C12N9/0075 , A01K2217/05 , A61K38/00 , A61K48/00
摘要： The present invention relates to new NOS variants or mutants which contain structural alterations in the site of Akt dependent phosphorylation. The altered NOS proteins or peptides, especially the human eNOS proteins or peptides, Akt proteins or polypeptides and their encoding nucleic acid molecules are useful as gene therapy agents for the treatment of diseases including post angioplasty restenosis, hypertension, atherosclerosis, heart failure, diabetes and diseases with defective angiogenesis. NOS proteins and peptides are also useful in methods of screening for agents which modulate NOS activity.
摘要翻译：本发明涉及新的NOS变体或突变体，其包含Akt依赖性磷酸化位点的结构改变。改变的NOS蛋白质或肽，特别是人eNOS蛋白质或肽，Akt蛋白质或多肽及其编码核酸分子可用作治疗包括血管成形术后再狭窄，高血压，动脉粥样硬化，心力衰竭，糖尿病等疾病的基因治疗剂具有血管生成不良的疾病 NOS蛋白质和肽也可用于筛选调节NOS活性的试剂的方法。

8. 发明申请

US20040120930A1 Gene therapy for critical limb ischemia with wild type or mutant eNOS 审中-公开
标题翻译：用野生型或突变型eNOS进行严重肢体缺血的基因治疗
公开(公告)号：US20040120930A1
公开(公告)日：2004-06-24
申请号：US10642255
申请日：2003-08-15
申请人： Schering Aktiengesellschaft
发明人： William P. Dole , Katalin Kauser , Hu Sheng Qian , Gabor Rubanyi
IPC分类号： A61K048/00
CPC分类号： C12N9/0075 , A61K48/00 , A61K48/005 , C12N2799/022
摘要： The present invention provides novel methods of preventing, diagnosing, and treating Critical Limb Ischemia (CLI), using eNOS polypeptides and polynucleotides to modulate eNOS activity in cells. Wild-type and mutant eNOS polypeptides, and polynucleotides encoding such polypeptides, are provided for use in the methods of the present invention. The eNOS mutant polypeptides of the present invention have at least one mutation corresponding to a site in a functional domain of a mammalian eNOS that is phosphorylated in cells.
摘要翻译：本发明提供使用eNOS多肽和多核苷酸调节细胞中eNOS活性的临床肢体缺血（CLI）的预防，诊断和治疗的新方法。提供野生型和突变体eNOS多肽，以及编码这种多肽的多核苷酸，用于本发明的方法。本发明的eNOS突变体多肽具有至少一个对应于在细胞中被磷酸化的哺乳动物eNOS的功能域中的位点的突变。

9. 发明申请

US20040082659A1 Enhancement of vascular function by modulation of endogenous nitric oxide production or activity 审中-公开
标题翻译：通过调节内源性一氧化氮的产生或活性来增强血管功能
公开(公告)号：US20040082659A1
公开(公告)日：2004-04-29
申请号：US10618835
申请日：2003-07-15
申请人： The Board of Trustees of the Leland Stanford Junior University
发明人： John P. Cooke , Victor J. Dzau , Gary H. Gibbons
IPC分类号： A61K031/198 , A61K038/00
CPC分类号： A61K31/00 , A23L33/175 , A23V2002/00 , A61K31/195 , A61K31/198 , A61K38/063 , A61K45/06 , A61K48/00 , A61K48/0075 , C12N9/0044 , C12N9/0075 , C12N15/85 , C12N2800/107 , A23V2250/0606 , A23V2200/326 , A23V2200/3262 , A61K2300/00
摘要： Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. Alternatively, or in combination, other compounds may be administered which provide for short term enhancement of nitric oxide, either directly or by physiological processes
摘要翻译：维持或改善血管功能和结构，长期施用生理上可接受的化合物，其增强宿主中NO诱导的松弛途径中的内源性一氧化氮或其它中间体的水平。或者或组合地，可以直接或通过生理过程施用提供一氧化氮短期增强的其它化合物

10. 发明申请

US20030031649A1 Gene therapy to promote angiogenesis 审中-公开
标题翻译：基因治疗促进血管生成
公开(公告)号：US20030031649A1
公开(公告)日：2003-02-13
申请号：US10136545
申请日：2002-05-01
发明人： Anton Jan van Zonneveld , Stefan Frederik Franciscus Verlinden
IPC分类号： A61K048/00 , C12N015/869
CPC分类号： C12N7/00 , A61K38/00 , A61K38/1709 , A61K38/1825 , A61K38/1866 , A61K38/1891 , A61K38/45 , A61K48/00 , C12N9/0075 , C12N15/86 , C12N2710/10343 , C12N2710/10352 , C12N2810/6018 , C12N2830/00 , C12N2830/15 , C12N2830/60 , C12N2840/203 , A61K2300/00
摘要： A nucleic acid delivery vehicle for enhancing and/or inducing angiogenesis. This nucleic acid delivery vehicle includes a nucleic acid having at least one sequence coding for a protein capable of increasing nitric oxide production and a nucleic acid delivery carrier. The vehicle can be used in a method for enhancing and/or inducing angiogenesis in an individual involving providing cells of the individual with the nucleic acid delivery vehicle. Also disclosed is a cell for producing the nucleic acid delivery vehicle for enhancing and/or inducing angiogenesis. As before, the nucleic acid delivery vehicle includes a nucleic acid having at least one sequence coding for a protein capable of increasing nitric oxide production and a nucleic acid delivery carrier wherein the nucleic acid delivery carrier includes a virus vector selected from the group of adenoviral vectors and adeno-associated viral vectors, the cell comprising means for producing the virus vector in the absence of replication competent adenovirus and adeno-associated virus.
摘要翻译：用于增强和/或诱导血管生成的核酸递送载体。该核酸递送载体包括具有编码能够增加一氧化氮产生的蛋白质的至少一个序列的核酸和核酸递送载体。载体可用于增强和/或诱导个体中血管生成的方法，所述个体涉及提供个体的细胞与核酸递送载体。还公开了用于生产用于增强和/或诱导血管生成的核酸递送载体的细胞。如前所述，核酸递送载体包含具有编码能够增加一氧化氮产生的蛋白质的至少一个序列的核酸和核酸递送载体，其中所述核酸递送载体包含选自腺病毒载体的病毒载体和腺相关病毒载体，所述细胞包含在不存在复制感受态腺病毒和腺相关病毒的情况下产生病毒载体的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式